Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that the launch of Neurochem's Alzhemed (NC-758) and Myriad Genetics' Flurizan (R-flurbiprofen) will be the primary drivers in growing the dementia drug treatment market by 11% annually over the next ten years. The new Pharmacor report, Strategic Overview of the Dementia Drug Market 2004-2014, forecasts that by 2014 Alzhemed and Flurizan, the first disease-modifying treatments for dementia, will account for 57% of drug sales in this market.

The report also finds that sales of acetylcholinesterase inhibitors including Eisai/Pfizer's Aricept, Novartis's Exelon, and Shire/Janssen's Razadyne, as well as the N-methyl-D-aspartate receptor antagonist memantine -- Merz's Axura, Lundbeck's Ebixa, and Forest Laboratories' Namenda -- will decline significantly between 2009 and 2014.

"During the next five years, we forecast that currently-available therapies will expand their labels to include other forms of dementia," said Andrea Witt, Ph.D., analyst at Decision Resources, Inc. "These added approvals are expected to expand the use of these drugs, both on- and off- label, and will increase their competitive advantage over other agents in the market. However, this expanded labeling will not be enough to soften the blow of impending generic erosion and the launches of Alzhemed and Flurizan."

About Dementia

Dementia is a group of diseases that have different etiologies and pathophysiologies, including vascular dementia, Lewy body dementia, fronto- temporal dementia, and Alzheimer's disease. Epidemiological evidence suggests that many patients suffer from multiple forms of dementia.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact: Elizabeth Marshall                                  Decision Resources, Inc.                                  781-296-2563                         

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,

Humana's Bold Move to Dominate the Managed Medicare Market

View Now